Results

1–10 of 52 results for Gene Therapy

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: Phase 2 LUNA Study Update
Glenn C. Yiu, MD, PhD
Updates from the Field
2025
Multicenter Randomized Sham-Controlled Double-Masked Phase 2b Clinical Trial of Multi-Characteristic Opsin in Patients With Advanced Retinitis Pigmentosa
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2022
One Year Follow-Up in a Phase ½ Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Updates from the Field
2024
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2022
Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2022
ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2022
Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa: Phase 2 Randomized Controlled Masked Multicenter Clinical Trial (Skyline) Interim Safety Results
On Demand Cases, Courses, and Papers
2022
Safety and Efficacy of Intravitreal Optogenetic Gene Therapy for Advanced Retinitis Pigmentosa
Sai H Chavala, MD
On Demand Cases, Courses, and Papers
2021